Literature DB >> 30227386

Epigenetic crossroads of the Epstein-Barr virus B-cell relationship.

Thomas C Frost1, Benjamin E Gewurz2.   

Abstract

Epstein-Barr virus (EBV) is a gamma-herpesvirus that establishes lifelong infection in the majority of people worldwide. EBV uses epigenetic reprogramming to switch between multiple latency states in order to colonize the memory B-cell compartment and to then periodically undergo lytic reactivation upon plasma cell differentiation. This review focuses on recent advances in the understanding of epigenetic mechanisms that EBV uses to control its lifecycle and to subvert the growth and survival pathways that underly EBV-driven B-cell differentiation versus B-cell growth transformation, a hallmark of the first human tumor virus. These include the formation of viral super enhancers that drive expression of key host dependency factors, evasion of tumor suppressor responses, prevention of plasmablast differentiation, and regulation of the B-cell lytic switch.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30227386      PMCID: PMC6263794          DOI: 10.1016/j.coviro.2018.08.012

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  74 in total

1.  AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome.

Authors:  Markus Kalla; Anne Schmeinck; Martin Bergbauer; Dagmar Pich; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

2.  Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

3.  Mouse model for acute Epstein-Barr virus infection.

Authors:  Tristan Wirtz; Timm Weber; Sven Kracker; Thomas Sommermann; Klaus Rajewsky; Tomoharu Yasuda
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-16       Impact factor: 11.205

4.  Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers.

Authors:  Denes Hnisz; Jurian Schuijers; Charles Y Lin; Abraham S Weintraub; Brian J Abraham; Tong Ihn Lee; James E Bradner; Richard A Young
Journal:  Mol Cell       Date:  2015-03-19       Impact factor: 17.970

5.  Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.

Authors:  S Zalani; E Holley-Guthrie; S Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

6.  The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.

Authors:  Shuvomoy Banerjee; Jie Lu; Qiliang Cai; Abhik Saha; Hem Chandra Jha; Richard Kuo Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

7.  EBV latency types adopt alternative chromatin conformations.

Authors:  Italo Tempera; Michael Klichinsky; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

8.  Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of B Cells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas.

Authors:  Katerina Vrzalikova; Sarah Leonard; Yichao Fan; Andrew Bell; Martina Vockerodt; Patrik Flodr; Kenneth L Wright; Martin Rowe; Qian Tao; Paul G Murray
Journal:  Pathogens       Date:  2012-10-08

9.  An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation.

Authors:  Yonggang Pei; Shuvomoy Banerjee; Hem Chandra Jha; Zhiguo Sun; Erle S Robertson
Journal:  PLoS Pathog       Date:  2017-07-24       Impact factor: 6.823

10.  EBV persistence without its EBNA3A and 3C oncogenes in vivo.

Authors:  Anita Murer; Donal McHugh; Nicole Caduff; Jens Kalchschmidt; Mario Barros; Andrea Zbinden; Riccarda Capaul; Gerald Niedobitek; Martin Allday; Obinna Chijioke; Christian Münz
Journal:  PLoS Pathog       Date:  2018-04-30       Impact factor: 6.823

View more
  11 in total

Review 1.  Vaccination against the Epstein-Barr virus.

Authors:  Julia Rühl; Carol S Leung; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2020-05-04       Impact factor: 9.261

Review 2.  The Global Landscape of EBV-Associated Tumors.

Authors:  Claire Shannon-Lowe; Alan Rickinson
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

3.  A multi-omics approach to Epstein-Barr virus immortalization of B-cells reveals EBNA1 chromatin pioneering activities targeting nucleotide metabolism.

Authors:  R Jason Lamontagne; Samantha S Soldan; Chenhe Su; Andreas Wiedmer; Kyoung Jae Won; Fang Lu; Aaron R Goldman; Jayamanna Wickramasinghe; Hsin-Yao Tang; David W Speicher; Louise Showe; Andrew V Kossenkov; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2021-01-26       Impact factor: 6.823

4.  Nonsense-mediated decay controls the reactivation of the oncogenic herpesviruses EBV and KSHV.

Authors:  Michiel van Gent; Adrian Reich; Sadanandan E Velu; Michaela U Gack
Journal:  PLoS Biol       Date:  2021-02-17       Impact factor: 8.029

Review 5.  The Role of Lytic Infection for Lymphomagenesis of Human γ-Herpesviruses.

Authors:  Christian Münz
Journal:  Front Cell Infect Microbiol       Date:  2021-03-26       Impact factor: 5.293

Review 6.  Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.

Authors:  Takayuki Murata; Atsuko Sugimoto; Tomoki Inagaki; Yusuke Yanagi; Takahiro Watanabe; Yoshitaka Sato; Hiroshi Kimura
Journal:  Viruses       Date:  2021-11-23       Impact factor: 5.048

Review 7.  Epigenetic lifestyle of Epstein-Barr virus.

Authors:  Alexander Buschle; Wolfgang Hammerschmidt
Journal:  Semin Immunopathol       Date:  2020-03-30       Impact factor: 9.623

Review 8.  Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice.

Authors:  Christian Münz
Journal:  Vaccines (Basel)       Date:  2019-12-17

9.  Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.

Authors:  Yuchen Zhang; Chang Jiang; Stephen J Trudeau; Yohei Narita; Bo Zhao; Mingxiang Teng; Rui Guo; Benjamin E Gewurz
Journal:  mBio       Date:  2020-10-27       Impact factor: 7.867

10.  Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.

Authors:  Mark Manzano; Thomas Günther; Hyunwoo Ju; John Nicholas; Elizabeth T Bartom; Adam Grundhoff; Eva Gottwein
Journal:  mBio       Date:  2020-08-25       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.